Sec. 313. Preemption of State barriers to the substitution of biosimilar products
44 words·~1 min read·
/bill/116/hr/1332/ih/section-313A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
No State, or any political subdivision thereof, may, under any circumstances, prohibit a pharmacy or pharmacist from dispensing, in place of a biological reference product, any biosimilar that the Food and Drug Administration has designated as an interchangeable product for that biological reference product.